Several healthcare organisations strongly recommend aspirin usage for high-risk patients to prevent cardiovascular disease. This study retrospectively audited the usage of aspirin as an antiplatelet agent in two cohorts of Australian residential aged care facility (RACF) residents in the Perth, Western Australia (WA) and Sydney, New South Wales (NSW) metropolitan and surrounding areas. The primary objective was to compare the appropriateness of current practice regarding aspirin usage with the National Heart Foundation of Australia (NHF) guidelines. The secondary objective was to identify predictors of aspirin usage and non-usage to permit targeting of 'at risk' groups.
Introduction
Acetylsalicylic acid, commonly known as aspirin, was discovered more than 100 years ago and was used initially for its analgesic, anti-inflammatory and antipyretic properties. It is only in the past 25 years that its effectiveness as an antiplatelet agent in the prevention of myocardial infarction and ischaemic stroke has been recognised. 1 Aspirin is commonly used as an antiplatelet agent in doses of 75mg to 150mg daily, which have been found to be at least as effective as higher doses. 2 A recent review article, however, recommended that the aspirin dose for cardiovascular disease prevention should be between 75mg and 81mg daily to minimise the risks of gastrointestinal bleeding and other bleeding complications. 3 Aspirin use for the primary and secondary prevention of cardiovascular events remains one of the most controversial issues in the medical literature, but numerous trials have clearly demonstrated a role for aspirin in a variety of patient groups. In primary prevention, gender effects are apparent, with males benefiting from a 32% reduction (relative to non-aspirin users) in the risk of myocardial infarction and females from a relative 17% reduction in ischaemic stroke. 4 Benefits have also been noted in high risk diabetic patients, although the magnitude of the risk reduction is much lower than in non-diabetic patients. 2, 5 The lower risk reduction in the diabetic subjects might be due to the dyslipidemia leading to endothelial dysfunction, up-regulation of inflammatory responses and increased platelet turnover. 5, 6 Aspirin therapy is also effective for secondary prevention of occlusive vascular events in high-risk patients, including patients with myocardial infarction, ischaemic stroke, angina or atrial fibrillation (AF). A recent meta-analysis of antiplatelet therapy, where aspirin was the most commonly used agent, demonstrated a reduction in the combined outcome of any serious vascular event and nonfatal stroke, non-fatal myocardial infarction and vascular mortality. Furthermore, the absolute benefits in various high-risk categories greatly outweighed the absolute risks of major extracranial bleeding. 2 In view of evidence supporting aspirin usage in the primary and secondary prevention of cardiovascular diseases, various British organisations, the National Heart Foundation of Australia (NHF), the American Heart Association and American Diabetes Association have recommended aspirin for patients at high risk of cardiovascular disease. [7] [8] [9] [10] The NHF recommends that all patients with coronary heart disease and other manifestations of atherosclerosis (e.g. stroke and peripheral arterial disease) be prescribed aspirin at 75mg to 150mg per day unless contraindicated. 8, 11 Other authors have refined these recommendations, suggesting that aspirin should only be used for primary prevention of cardiovascular disease in asymptomatic patients who are deemed to be at more than 1% annual risk of cardiovascular disease using standard coronary risk algorithms. 12 Detailed consideration of an individual's cardiovascular risk and potential benefits versus harm are therefore essential before aspirin therapy is prescribed. 9, 12 Despite the proven benefits of aspirin therapy in reducing cardiovascular risk, aspirin usage in patients with or at risk of cardiovascular disease, especially in community settings, is still lower than desired. Surveys in diabetic populations, either with or without a history of coronary artery disease, have revealed that only approximately 20% of such patients take regular aspirin. 13, 14 Other studies have revealed that only about half of the patients with a history of myocardial infarction, angina or peripheral arterial disease receive antiplatelet therapy. 2 Although one recent study reported an increase in aspirin usage, only 32.8% of high-risk patients were on aspirin. 15 As age substantially increases cardiovascular risk, 16, 17 it is especially important to ensure that aspirin is appropriately prescribed in older patient populations. Studies in older populations have revealed similar results to those in younger patient groups, including one primary prevention study that found rates of aspirin use of 32% overall and 37% in those at highest cardiovascular risk. 28 Only 22.5% of Australians over 70 years of age screened as part of a recent pilot study were taking aspirin, although this may have represented some degree of under-reporting. 29 Aspirin usage in the community, including by community-dwelling older patients, thus appears suboptimal. There are, however, currently no published data regarding the use of aspirin among the elderly Australian population residing in residential aged care facilities (RACFs) who, because of their age, are likely to be at significant cardiovascular risk. Based on the rates of usage among their community-dwelling counterparts, it was hypothesised that less than optimal aspirin use may be occurring in this population. This may represent a significant gap between evidence and practice which, if addressed, may improve the clinical outcomes of these patients. This study therefore aimed to audit the usage of aspirin as an antiplatelet agent amongst two populations of RACF residents, in Western Australia (WA) and New South Wales (NSW), to determine the appropriateness of current practice against the NHF guidelines. The secondary objective of the study was to identify the predictors of aspirin usage (including residents' characteristics, and concomitant drugs or comorbidities suggestive of indications for aspirin therapy) and aspirin non-usage (for example, factors that may predispose a resident to gastrointestinal, intracranial or other bleeding) in these groups. It was hoped that this would permit recommendations targeted at specific patient groups to be made to promote appropriate aspirin usage in the RACF-dwelling elderly.
Methods
This study was a retrospective audit utilising two available data sets. Part One used a convenience sample of residential medication management review records of 201 WA RACF residents supplied by a single accredited pharmacist. All of the RACFs were within the Perth metropolitan and surrounding area. Part Two of the study involved the de-identified 2007 medication supply records of 791 RACF residents from the Sydney, NSW, metropolitan area which were randomly selected from Manrex, a private company specialised in medication delivery systems. Although the information available from the NSW supply records was not as comprehensive as that included in the WA medication management reviews, analysis of this larger data set was undertaken to validate, and thus confirm the generalisability of, the findings from the WA records, and to contribute statistical power to the results.
All available records were included in the analysis, excepting those of residents who met the exclusion criteria of being less than 65 years of age, or having a documented history of aspirin intolerance or allergy. The minimum age limit was to ensure that the majority of the residents would be at least at moderate risk of a cardiovascular event (i.e. with a 10 -15% 5 year risk of histamine -2 -receptor antagonists (H 2 RAs) and antacids. All thiazides and thiazide-like antihypertensives were included in the "thiazides" category while amiloride, clonidine, hydralazine and prazosin were included in the "others" category within antihypertensives. Enoxaparin and heparin were included in "others" category within anticoagulants. For Part Two of the study, only information regarding the NSW residents' age, gender and medication usage was available and was recorded as above.
Statistical analyses were performed using SPSS 15.0 for Windows (Chicago, IL, USA). Baseline characteristics of the RACF residents were analysed using independent samples t-testing for continuous variables and χ 2 testing for categorical variables. Odds ratios for aspirin usage among the RACF residents and their 95% confidence intervals were calculated using univariate and multivariate binary logistic regression. A p value of less than 0.05 was judged as statistically significant for all analyses.
Results

PART ONE
Of the initial 201 WA residents, two were excluded as they were less than 65 years old, resulting in a final cohort of 199 residents. The baseline characteristics of the subjects are presented in Table 1 .
Fourteen of the RACFs were in the Perth metropolitan area, while three were in surrounding areas.
The residents were under the care of 70 doctors (an average of 2.8 residents per doctor) which was deemed sufficient to prevent confounding due to prescribing bias. The most common medical conditions among the WA RACF residents were hypertension (n = 108; 54.3%), followed by stroke (n = 52; 26.1%) and ischaemic heart disease (n = 49; 24.6%).
Overall, 70 residents (35.2%) were on either aspirin alone (92.9%) or combined aspirin-dipyridamole (7.1%). The common aspirin dosages used were 100mg and 150mg daily. Apart from one resident who used aspirin at 25mg daily, the dose of aspirin used was as recommended by the NHF guidelines (75mg to 150mg daily). 8 Although the NHF recommends aspirin for all patients with ischaemic heart disease, stroke or peripheral arterial disease, 8 none of these medical conditions which were potential indicators of aspirin usage had a proportion of aspirin usage higher than 50%. Rates of aspirin prescribing varied from 23.1% for diabetics, to 42.9%, 46.2% and 47.1% for those patients with ischaemic heart disease, stroke or peripheral arterial disease, respectively.
There was no significant age difference between aspirin users and non-users (p=0.55), and the location of the RACF also failed to influence aspirin use (p=0.082). Results of the univariate analysis of the WA data ( Table 2 ) also showed that the resident's age did not affect the odds of aspirin usage.
None of the other potential predictors of aspirin usage and non-usage, either concurrent drug therapy or disease states, demonstrated a significant influence on aspirin use in binary logistic regression analyses (WA section of Table 2 and Table 3 ).
PART TWO
Nineteen of the 791 NSW RACFs residents were excluded as they failed to meet the study's age criteria, giving a final count of 772 residents from 17 different RACFs (Table 1 ). Similar to the WA residents, no significant age difference was found between aspirin users and non-users (p=0.886) within the NSW cohort.
The rate of aspirin usage in NSW failed to differ from that in WA (p = 0.476), with 251 (32.5%) of the NSW residents using aspirin. Once again, as in WA, the majority (226, 90.0%; p = 0.352) was using aspirin alone. The two common aspirin dosages used by the NSW RACF residents were the same as that of the WA cohort. Apart from one resident who was on aspirin at 25mg daily and three who were on dosages above 150mg daily, the dose of aspirin used was generally as recommended by the NHF. 8 Unlike the WA data, results of the univariate and multivariate analyses ( Table 2) showed that males were significantly more likely than females to use aspirin (p=0.021). Residents who were taking ARBs (p=0.030), ACEIs (p=0.001), beta-blockers (p<0.001) or antihyperlipidemics (p=0.026) were also more likely to use aspirin concurrently. However, patients who were taking either clopidogrel (p<0.001) or warfarin (p<0.001) were significantly less likely to use aspirin concurrently.
The characteristics of the WA and NSW residents were compared. There was no significant difference between the gender distributions (p=0.141), and although there was a difference in the ages, both groups were similarly elderly (86.48 years vs 92.13 years, p<0.001). Male NSW RACF residents were more likely than females to use aspirin (38.4% vs 30.5%, p=0.041), however, there was no significant difference in aspirin usage between the genders of the WA RACF residents (39% vs 34.2%, p=0.562).
The aspirin dosages used by RACF residents of both states was generally in accordance to the NHF recommendations 8 but the NSW cohort was prescribed a wider dosage range (25mg to 300mg) than the WA cohort. WA RACF residents were more likely than NSW residents to use aspirin at 150mg daily (9% vs 4.8%, p=0.021), thiazides (11.1% vs 6.2%, p=0.019) and aldosterone antagonists (7.5% vs 4.1%, p=0.047). However, they were less likely than NSW RACF residents to use antianginals (12.1% vs 18.5%, p=0.031) and PPIs, H 2 RAs and antacids (38.7% vs 47.4%, p=0.028).
Of these medications for which the usages differed between the cohorts, only antianginal usage was a significant predictor of aspirin usage in the NSW cohort. This was only in the univariate analysis, however, with no significant predictive value demonstrated in the multivariate analysis. In light of this, and the fact that both populations were similarly elderly, the NSW and WA data were combined for further analysis. The results of the multivariate analysis of the combined data, corrected for location, were, as expected, found to be similar to those from the NSW data due to its larger population ( Table 2) . Aspirin usage was not affected by age (p=0.571). Males were more likely than female to use aspirin (p=0.021). Patients who were on ARBs (p=0.027), ACEIs (p=0.001), betablockers (p<0.001), antianginals (p=0.045) or antihyperlipidemics (p=0.007) were significantly more likely to use aspirin concurrently. Although antiarrhythmic usage was a non-significant predictor of aspirin usage from the univariate analysis, it became a significant predictor of aspirin usage when multivariate analysis was performed (p=0.039). Patients who were on clopidogrel (p<0.001) or warfarin (p<0.001) were significantly less likely to be concurrent aspirin users.
Discussion
The results of this study showed that overall aspirin usage among this study population of 65 years and older RACF residents, more than 80% of who were at least 80 years old, was lower than desired according to the NHF guidelines. 8, 9, 12 This was despite the fact that these residents, by age alone, had at least a 5-10% absolute 5-year cardiovascular risk 17 and according to the NHF guidelines would have been potential candidates for aspirin therapy. 9, 12 Overall aspirin usage for the RACF residents in NSW and WA was only about 30%. Aspirin usage was 23.1% among diabetics, and ranged from 42.9% to 47.1% in secondary prevention.
These results mirrored those of previous studies that have demonstrated that, in spite of strong recommendations by various organisations for aspirin usage to prevent coronary heart disease in high-risk patients, 7-11 its usage by these patients, especially in the community setting, is still low in developed countries. 14, 15, 18 Stafford et al reported aspirin underutilisation in US ambulatory care for both primary and secondary prevention of cardiovascular disease, with prescribing rates of 32.8% for high risk patients and 11.7% for diabetic patients. 15 The current study, which was based on a more elderly and homogenous population as compared to the patients included in the study by Stafford et al (who were aged from 20 to more than 80 years old), reported a similar percentage of aspirin usage. Considering that the population of this study, based on age alone, would possibly have a higher overall cardiovascular risk, the aspirin usage for the population of this study should in fact have been much higher than that This study demonstrated that males were more likely than females to use aspirin among the WA, NSW and combined residents, although the results were not statistically significant for the WA group.
Similar results have been found in previous studies involving a rural diabetic population, 14 It is important to note that the WHS overall findings were based on a much younger subject group as compared to this study, with 89.7% of participants younger than 65 years old. 19 Therefore, the findings might not be fully relevant to the RACF residents. However, the subgroup analysis of women age 65 years old and above showed that aspirin usage was associated with significant reduction in major cardiovascular events (RR=0.74, p=0.008), ischaemic stroke (RR=0.70, p=0.05) and even myocardial infarction (RR=0.66, p=0.04) which was not seen in younger age groups. 19 Hence, in light of the available evidence, it would be reasonable to suggest that female patients 65 years and above should be treated with aspirin at least as intensively as the male patients for the primary prevention of cardiovascular disease.
With diabetes as one of the most common chronic disease worldwide 20, 21 and a leading cause of cardiovascular death, 22 the disease and its associated cardiovascular risk factors need to be addressed. 6 In spite of support for aspirin usage by various guidelines and clinical evidence, aspirin usage by diabetic patients is still low. US research revealed that less than a quarter of surveyed diabetic patients with coronary artery disease were on aspirin. 13 A Canadian study reported that only 23% of a rural diabetic population with a mean age of 62.9±12.5 years were antiplatelet (aspirin and/or clopidogrel) users. 14 Although this study population involved the institutionalised diabetic elderly who may have been more frequently followed up by doctors and would have possibly been at an even higher overall cardiovascular risk because of their advanced age, the proportion of aspirin usage was similar to that reported in the Canadian study. Hence, a significant effort will be necessary to encourage aspirin usage in this population. In the US, various initiatives have been implemented to reduce cardiovascular deaths in diabetic patients, one of which is to increase the proportion of diabetic patients who take aspirin at least 15 times per month from 20% to 30% by 2010. 22 Results of this study showed that the dosage of aspirin used by the elderly residents was generally in accordance with the NHF guidelines. 8, 9 It was important to note that current evidence supports the use of aspirin at doses between 75mg to 81mg daily. The effects of aspirin at doses lower than 75mg were less certain while any doses higher than 81mg did not suggest better prevention but might be associated with higher risks of gastrointestinal bleeding and other bleeding complications. 2, 3 The rationale for the few RACF residents being prescribed doses outside the NHF recommended range and the disparity between the NHF guidelines and the literature recommendations were not investigated as these issues were beyond the scope of this study.
Multivariate analysis of the combined data showed that beta-blocker usage was the strongest predictor for aspirin usage, followed by the use of ACEIs and ARBs. Other predictors of aspirin usage included antihyperlipidemics (which consisted mostly of statins) and antiarrhythmics (principally digoxin). These results might have been influenced by the effective implementation of guidelines for the long-term management of ischaemic heart disease (IHD) with concurrent aspirin, beta-blockers, ACEIs and statins. 11 Although there is stronger evidence supporting the use of warfarin compared to antiplatelet agents for stroke prevention in AF, the most common form of cardiac arrhythmia, this study suggested that the presence of AF was a moderately strong predictor for aspirin usage. 23 This may be explained by assuming that aspirin was prescribed in preference to warfarin in these elderly residents due to unrecorded contraindications to warfarin therapy, perceived increased risks of cerebrovascular haemorrhage and falls or an unwillingness to undertake the monitoring associated with warfarin therapy. 30 While all of these are potential reasons for choosing aspirin over warfarin in this elderly population, due to the lack of available information, these hypotheses could not be verified.
Warfarin was a strong predictor of aspirin non-usage as the concurrent usage of these drugs might lead to a significant increase in bleeding risk. 3, 23, 24 Clopidogrel was also a predictor of aspirin nonusage as it is commonly used as an alternative by patients who are aspirin intolerant. 11, 25 Clopidogrel was a weaker predictor of aspirin non-usage than warfarin, however, because it is commonly used concurrently with aspirin for patients with unstable angina, recurrent cardiac events or those who have undergone stent implantation. 11 As noted in Table 1 , 15 of the WA residents (7.5%) and 65 (8.4%) of the NSW residents were taking the combination of aspirin and clopidogrel. Counterintuitively, neither the use of NSAIDs nor PPIs, H 2 RAs and antacids proved to be significant predictors of aspirin non-usage, with NSAID usage actually associated with non-significant increases in aspirin usage in all three data sets.
Various limitations of this study must be acknowledged. Throughout this discussion, it has been implied that the failure of a resident to receive aspirin equated to non-compliance with the NHF guidelines and thus suboptimal prophylaxis of cardiovascular disease. Aspirin remains the gold standard for this indication and was thus the focus of this investigation, so clopidogrel use was not routinely recorded. This may have resulted, however, in an under-reporting of compliance with the recommendations by failing to consider clopidogrel as a rational alternative for some patients. This omission is partially ameliorated, however, by the fact that the most common situation where clopidogrel would be prescribed as an alternative to aspirin would be in patients with aspirin intolerance or allergy, which was one of the exclusion criteria for this study.
There were some further logistical limitations to this study. The sample size of the WA cohort may have been too small to provide adequate statistical power to definitively determine the predictors of aspirin usage and non-usage. Convenience sampling, a potentially biased sampling method, was used to obtain the samples for this study. As the population was homogenous (based on the narrow age distribution), it is believed that this sampling technique would have had minimal adverse effect on the study results. The possibility of prescribing bias could not be ascertained from the NSW data as prescriber information was not available. Based on current GP-to-population ratios provided by the Australian Divisions of General Practice, it can be assumed that the resident to doctor ratio in NSW would have been sufficiently large to minimise any potential effect of prescribing bias on the NSW data. 26 The information collected on the residents' medical histories was reliant on the quality of the data recorded, which may have introduced some inaccuracies. For example, the term "CVA" might have been used for strokes of either ischaemic (a predictor of aspirin usage) or haemorrhagic (a predictor of aspirin non-usage) aetiology. However, this should not have affected significantly the analysis adversely considering that about 80% of Australian stroke patients suffer from ischaemic strokes. 27 The effect of race on aspirin usage could not be investigated as such information was not available from both WA and NSW data. Smoking status and vital statistics of the WA RACF residents such as height, weight and blood pressure readings were also not available. As a result, the relevance of smoking, obesity and refractory hypertension as cardiovascular risk factors and predictors for aspirin usage could not be assessed. Due to this lack of information, plus an inability to assess an individual resident's potential bleeding risk, it was impossible to accurately determine each resident's risk benefit balance in relation to aspirin usage. The effect of other factors, such as individual resident's or prescriber's attitudes towards aspirin use, and the social, educational and economic considerations of drug use within RACFS, could also not be assessed. Such factors could be considered in a future study.
Conclusions
In conclusion, this study revealed a substantial gap between the evidence and practice for the care of institutionalised elderly patients at high risk of cardiovascular disease, with suboptimal aspirin usage among residents in both WA and NSW. Various predictors of aspirin usage and non-usage were identified. It can be seen from this study that significant efforts are required to encourage aspirin usage in the elderly population in accordance with the NHF guidelines. Continuing medical education for doctors may be conducted to maintain a more consistent practice with subsequent research to assess the trends in aspirin usage. Targeted interventions may especially be beneficial in patient subpopulations in which aspirin use is lower than average, including women and diabetics. With these efforts to encourage aspirin usage, it may be possible to reduce the cardiovascular disease and economic burden on this population and society as a whole.
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